Hepatitis C drug stocks back in play
April 19, 2012 at 13:14 PM EDT
Hepatitis C specialists Gilead, Idenix and Achillion were back in play Thursday, as investors reacted to positive data on Gilead’s experimental drug GS-7977.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.